<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Hypercholesterolemia in primary biliary cholangitis (primary biliary cirrhosis)
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Hypercholesterolemia in primary biliary cholangitis (primary biliary cirrhosis)
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Hypercholesterolemia in primary biliary cholangitis (primary biliary cirrhosis)
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Steven Flamm, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Andre A Kaplan, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Raoul Poupon, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sanjiv Chopra, MD, MACP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Keith D Lindor, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kristen M Robson, MD, MBA, FACG
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Sep 19, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION AND PREVALENCE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hypercholesterolemia is a common feature of primary biliary cholangitis (PBC; previously referred to as primary biliary cirrhosis) and other forms of cholestatic liver disease. The mechanism of hyperlipidemia in cholestatic disorders is different from that in other conditions because unusual lipoprotein particles, such as lipoprotein-X, may accumulate and levels of high-density lipoprotein cholesterol are typically elevated.
        </p>
        <p>
         Hypercholesterolemia (ie, cholesterol values above 200 mg/dL [5.2 mmol/L]) affects approximately 75 percent of patients with primary biliary cholangitis at presentation, but is not associated with an increased risk of atherosclerosis [
         <a href="#rid1">
          1-4
         </a>
         ]. However, patients with primary biliary cholangitis may have other independent risk factors for cardiovascular disease that require attention in the setting of normal life expectancy with
         <a class="drug drug_general" data-topicid="10033" href="/z/d/drug information/10033.html" rel="external">
          ursodeoxycholic acid
         </a>
         treatment.
        </p>
        <p>
         This topic will review hypercholesterolemia in patients with primary biliary cholangitis. The pathogenesis and management of hypercholesterolemia and its role in the development of atherosclerosis are discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4553.html" rel="external">
          "Screening for lipid disorders in adults"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1506.html" rel="external">
          "Overview of established risk factors for cardiovascular disease"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/13603.html" rel="external">
          "Pathogenesis of atherosclerosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/112841.html" rel="external">
          "Management of low density lipoprotein cholesterol (LDL-C) in the secondary prevention of cardiovascular disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          CHOLESTEROL METABOLISM IN PBC
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hypercholesterolemia in primary biliary cholangitis is related to an increase in lipoprotein–X and a decrease in functional low-density lipoprotein (LDL) receptors.
        </p>
        <p class="headingAnchor" id="H3128722086">
         <span class="h2">
          Lipoprotein-X
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lipoprotein-X, an abnormal lipoprotein particle within the LDL region that is rich in free cholesterol and phospholipids, is increased in patients with cholestatic liver disease, including those with primary biliary cholangitis [
         <a href="#rid5">
          5-7
         </a>
         ]. Lipoprotein-X reduces the atherogenicity of LDL cholesterol by preventing LDL oxidation [
         <a href="#rid6">
          6
         </a>
         ]. Prolonged LDL oxidation has been demonstrated in patients with primary biliary cholangitis, and normalizes following liver transplantation [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2261096614">
         <span class="h2">
          Low-density lipoprotein receptors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Functional LDL receptors are decreased in injured hepatocytes, which leads to elevated serum cholesterol levels in patients with cholestatic liver disease, despite decreased cholesterol synthesis [
         <a href="#rid7">
          7
         </a>
         ]. Cholestasis leads to reduced bile acid secretion, which results in diminished synthesis of both bile acids and hepatic cholesterol, but this does not result in reduced serum cholesterol levels because of the decline in LDL receptors.
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          CLINICAL FEATURES
         </span>
        </p>
        <p class="headingAnchor" id="H2995900829">
         <span class="h2">
          Signs and symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with primary biliary cholangitis and hypercholesterolemia may present with plane xanthomas, which are soft, yellow, thin plaques found most commonly around the eyelids (xanthelasma), neck, trunk, shoulders, and axillae  (
         <a class="graphic graphic_picture graphicRef67919" href="/z/d/graphic/67919.html" rel="external">
          picture 1
         </a>
         ). Xanthoma can also occur on the palms, soles, tendon sheaths, bony prominences, and peripheral nerves [
         <a href="#rid8">
          8
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3621.html" rel="external">
          "Clinical manifestations, diagnosis, and prognosis of primary biliary cholangitis"
         </a>
         .)
        </p>
        <p>
         Affected patients may complain about the appearance of these lesions, which are usually asymptomatic. (See
         <a class="local">
          'Treatment for xanthomas'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/13786.html" rel="external">
          "Cutaneous xanthomas", section on 'Plane xanthomas'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H856544396">
         <span class="h2">
          Laboratory findings
         </span>
         <span class="headingEndMark">
          —
         </span>
         Serum cholesterol levels may exceed 1000 mg/dL (26 mmol/L) in patients with xanthomas [
         <a href="#rid7">
          7
         </a>
         ]. Xanthomas, but not xanthelasmas, correlate with total plasma cholesterol levels.
        </p>
        <p>
         Patients in the early stages of primary biliary cholangitis often have mild elevations of low-density and very-low-density lipoproteins and striking elevations of high-density lipoproteins (HDL) [
         <a href="#rid9">
          9
         </a>
         ]. HDL levels tend to decrease in the later stages of the disease, while triglyceride levels are often elevated [
         <a href="#rid7">
          7
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3621.html" rel="external">
          "Clinical manifestations, diagnosis, and prognosis of primary biliary cholangitis", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          RISK OF CARDIOVASCULAR DISEASE
         </span>
         <span class="headingEndMark">
          —
         </span>
         The risk of cardiovascular disease in patients with primary biliary cholangitis and hypercholesterolemia is generally not increased [
         <a href="#rid2">
          2,3,7,10
         </a>
         ]. In a large study which included 930 patients with primary biliary cholangitis, the risk of myocardial infarction, stroke, or transient ischemic attack was not increased compared with an age- and sex-matched control group (HRs in patients with primary biliary cholangitis compared with controls were for myocardial infarction HR 1.04 [95% CI 0.67-1.62], stroke HR 0.98 [95% CI 0.73-1.31], and transient ischemia attack HR 0.66 [95% CI 0.38-1.16]) [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         However, these patients may have other, independent risk factors for cardiovascular disease (eg, family history of coronary artery disease, diabetes mellitus, hypertension, or metabolic syndrome). Patients with primary biliary cholangitis should be screened for risk factors for cardiovascular disease, and patients with both primary biliary cholangitis and metabolic syndrome are at increased risk of cardiovascular disease. (See
         <a class="medical medical_review" href="/z/d/html/1784.html" rel="external">
          "Metabolic syndrome (insulin resistance syndrome or syndrome X)", section on 'Clinical evaluation and implications of diagnosis'
         </a>
         and
         <a class="local">
          'Clinical and laboratory monitoring'
         </a>
         below.)
        </p>
        <p>
         In a study of 171 patients with primary biliary cholangitis who responded to treatment with
         <a class="drug drug_general" data-topicid="10033" href="/z/d/drug information/10033.html" rel="external">
          ursodeoxycholic acid
         </a>
         with follow-up of over 10 years, the risk of cardiovascular disease was higher in patients who fulfilled criteria for metabolic syndrome (ie, any three of five possible risk factors: hyperglycemia, low HDL cholesterol, elevated triglycerides, obesity, hypertension)  (
         <a class="graphic graphic_table graphicRef53446" href="/z/d/graphic/53446.html" rel="external">
          table 1
         </a>
         ) compared with patients who did not have metabolic syndrome (29 versus 5 percent) [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          MANAGEMENT
         </span>
        </p>
        <p class="headingAnchor" id="H4114528915">
         <span class="h2">
          Clinical and laboratory monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         We routinely screen patients with primary biliary cholangitis for metabolic syndrome by measuring blood pressure, waist circumference, fasting lipid profile, and fasting glucose.
        </p>
        <p>
         We obtain a fasting lipid profile in all patients with primary biliary cholangitis at presentation and every two years thereafter. If the patient meets criteria for metabolic syndrome as defined by the National Cholesterol Education Program’s Adult Treatment Panel III report  (
         <a class="graphic graphic_table graphicRef53446" href="/z/d/graphic/53446.html" rel="external">
          table 1
         </a>
         ), we obtain a fasting lipid profile annually. The overall approach for monitoring patients with primary biliary cholangitis is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3623.html" rel="external">
          "Overview of the management of primary biliary cholangitis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2159885434">
         <span class="h2">
          Candidates for lipid lowering agents
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with primary biliary cholangitis (PBC), the efficacy of drug therapy for PBC in lowering cardiovascular morbidity and mortality is uncertain [
         <a href="#rid3">
          3,7
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="10033" href="/z/d/drug information/10033.html" rel="external">
          Ursodeoxycholic acid
         </a>
         and
         <a class="drug drug_general" data-topicid="108368" href="/z/d/drug information/108368.html" rel="external">
          obeticholic acid
         </a>
         are used in the management of PBC, and these drugs also reduce lipid levels. Ursodeoxycholic acid, the mainstay of treatment for primary biliary cholangitis, results in decreased levels of total and low density lipoprotein (LDL) cholesterol in patients with primary biliary cholangitis [
         <a href="#rid12">
          12,13
         </a>
         ]. This effect is mediated through increased catabolism of cholesterol into primary bile acids and reduced intestinal absorption of cholesterol [
         <a href="#rid14">
          14
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3623.html" rel="external">
          "Overview of the management of primary biliary cholangitis", section on 'Initial therapy'
         </a>
         .)
        </p>
        <p>
         Treatment with
         <a class="drug drug_general" data-topicid="108368" href="/z/d/drug information/108368.html" rel="external">
          obeticholic acid
         </a>
         decreases total and high-density lipoprotein (HDL) cholesterol [
         <a href="#rid15">
          15
         </a>
         ]. In a three month trial of 165 patients with primary biliary cholangitis, total cholesterol and HDL cholesterol levels decreased in a dose-dependent fashion in patients treated with obeticholic acid compared with those given placebo (eg, decrease in total cholesterol of 3, 5, and 13 percent in patients on obeticholic acid 10-mg, 25 mg or 50 mg, respectively). The mean HDL at the end of the trial was 56 mg/dL, and the lower limit of the range was above 40 mg/dL. (See
         <a class="medical medical_review" href="/z/d/html/3623.html" rel="external">
          "Overview of the management of primary biliary cholangitis", section on 'Subsequent therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H432406793">
         <span class="h3">
          Use of statins or fibrates
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lipid-lowering agents result in mild to moderate reductions in cholesterol levels in patients with primary biliary cholangitis. Our approach is the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with persistent cholestasis despite treatment with
         <a class="drug drug_general" data-topicid="10033" href="/z/d/drug information/10033.html" rel="external">
          ursodeoxycholic acid
         </a>
         (ie, total bilirubin level &gt;1.75 mg/dL or 30 microm/L), we use fibrates (eg,
         <a class="drug drug_general" data-topicid="8696" href="/z/d/drug information/8696.html" rel="external">
          bezafibrate
         </a>
         400 mg once daily [not available in the United States] or
         <a class="drug drug_general" data-topicid="91482" href="/z/d/drug information/91482.html" rel="external">
          fenofibrate
         </a>
         ) in combination with ursodeoxycholic acid (UDCA). We typically target a daily dose in the range of 100 to 150 mg of micronized fenofibrate, but specific dosing depends on the formulation as there are several preparations with different bioavailability [
         <a href="#rid16">
          16,17
         </a>
         ]. Detailed recommendations are available separately in the fenofibrate drug information monograph.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Fibrate therapy has been associated with reductions total serum cholesterol, non-high density lipoprotein cholesterol, and triglycerides but without increases in serum alanine aminotransferase or alkaline phosphatase [
         <a href="#rid17">
          17-20
         </a>
         ]. In a trial including 100 patients with PBC and incomplete biochemical response to UDCA,
         <a class="drug drug_general" data-topicid="8696" href="/z/d/drug information/8696.html" rel="external">
          bezafibrate
         </a>
         plus UDCA resulted in a greater reduction in total cholesterol level after 24 months compared with placebo plus UDCA (difference in median percent change from baseline cholesterol: -16 percentage points, 95% CI -23 to -9 percentage points) [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients who have elevated total and/or LDL cholesterol associated with metabolic syndrome and who have normal liver enzymes, statins may be used. We have no preference for a particular statin, and we monitor the liver enzymes annually in these patients. (See
         <a class="medical medical_review" href="/z/d/html/4549.html" rel="external">
          "Low-density lipoprotein cholesterol-lowering therapy in the primary prevention of cardiovascular disease", section on 'Indications for statin therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Because many of the statins (eg,
         <a class="drug drug_general" data-topicid="9575" href="/z/d/drug information/9575.html" rel="external">
          lovastatin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9923" href="/z/d/drug information/9923.html" rel="external">
          simvastatin
         </a>
         ,
         <a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">
          atorvastatin
         </a>
         , and
         <a class="drug drug_general" data-topicid="10282" href="/z/d/drug information/10282.html" rel="external">
          rosuvastatin
         </a>
         ) are excreted into bile, levels may accumulate in patients with primary biliary cholangitis and may lead to toxicity. Thus, statins should be avoided in patients with significant cholestasis (ie, total bilirubin level &gt;1.75 mg/dL [30 microm/L]) [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
         Data for most statins in patients with primary biliary cholangitis are limited to case series [
         <a href="#rid14">
          14,21,22
         </a>
         ]. In a four-week study including 15 patients with primary biliary cholangitis,
         <a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">
          atorvastatin
         </a>
         was associated with reductions in serum cholesterol and low-density lipoprotein cholesterol levels by 35 and 49 percent, respectively [
         <a href="#rid23">
          23
         </a>
         ]. However, 3 of 15 patients (20 percent) had increases in serum alanine aminotransferase levels by two to three times the upper limit of normal.
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Treatment for xanthomas
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cutaneous xanthomas associated with hypercholesterolemia are usually asymptomatic, although treatment may be desired for cosmetic reasons. Pharmacologic treatment of dyslipidemia often leads to improvement in xanthomas caused by hyperlipidemia. The treatment of cutaneous xanthomas is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/13786.html" rel="external">
          "Cutaneous xanthomas", section on 'Treatment'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2137523485">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/112041.html" rel="external">
          "Society guideline links: Primary biliary cholangitis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Background
         </strong>
         – Hypercholesterolemia (cholesterol values above 200 mg/dL [5.2 mmol/L]) affects approximately 75 percent of patients with primary biliary cholangitis at presentation, but it is not associated with an increased risk of atherosclerosis in these patients. (See
         <a class="local">
          'Introduction and prevalence'
         </a>
         above and
         <a class="local">
          'Risk of cardiovascular disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical features
         </strong>
         – Patients with primary biliary cholangitis and hypercholesterolemia may present with xanthomas, which are soft, yellow plaques found most commonly around the eyelids (xanthelasma), neck, trunk, shoulders, and axillae  (
         <a class="graphic graphic_picture graphicRef67919" href="/z/d/graphic/67919.html" rel="external">
          picture 1
         </a>
         ). Affected patients may complain about the appearance of these lesions, which are usually asymptomatic. (See
         <a class="local">
          'Clinical features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical and laboratory monitoring
         </strong>
         – For all patients with primary biliary cholangitis, we obtain a fasting lipid profile at presentation and every two years thereafter, and we screen patients for features of metabolic syndrome.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients with primary biliary cholangitis who meet criteria for metabolic syndrome, we obtain lipid profiles annually. (See
         <a class="local">
          'Clinical and laboratory monitoring'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Use of lipid lowering agents
         </strong>
         – For patients with primary biliary cholangitis who have elevated total and/or low density lipoprotein cholesterol associated with metabolic syndrome and who have normal liver enzymes, statins may be used. We monitor liver enzymes annually in these patients. (See
         <a class="local">
          'Use of statins or fibrates'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients with primary biliary cholangitis and independent risk factors for cardiovascular disease are managed with a standard approach that is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1546.html" rel="external">
          "Atherosclerotic cardiovascular disease risk assessment for primary prevention in adults: Our approach"
         </a>
         .)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Longo M, Crosignani A, Battezzati PM, et al. Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis. Gut 2002; 51:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Solaymani-Dodaran M, Aithal GP, Card T, West J. Risk of cardiovascular and cerebrovascular events in primary biliary cirrhosis: a population-based cohort study. Am J Gastroenterol 2008; 103:2784.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carey EJ, Ali AH, Lindor KD. Primary biliary cirrhosis. Lancet 2015; 386:1565.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loaeza-Del Castillo AM, Gaytán-Santillán A, López-Tello A, et al. Patterns of serum lipids derangements and cardiovascular risk assessment in patients with primary biliary cholangitis. Ann Hepatol 2019; 18:879.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Su TC, Hwang JJ, Kao JH. Hypercholesterolemia in primary biliary cirrhosis. N Engl J Med 2007; 357:1561.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang PY, Lu SC, Su TC, et al. Lipoprotein-X reduces LDL atherogenicity in primary biliary cirrhosis by preventing LDL oxidation. J Lipid Res 2004; 45:2116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sorokin A, Brown JL, Thompson PD. Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: a systematic review. Atherosclerosis 2007; 194:293.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jia Y, Liu L, Deng B, et al. Atypical primary biliary cholangitis results in vanishing bile duct syndrome with cutaneous xanthomas: a case report. Diagn Pathol 2022; 17:57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jahn CE, Schaefer EJ, Taam LA, et al. Lipoprotein abnormalities in primary biliary cirrhosis. Association with hepatic lipase inhibition as well as altered cholesterol esterification. Gastroenterology 1985; 89:1266.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Allocca M, Crosignani A, Gritti A, et al. Hypercholesterolaemia is not associated with early atherosclerotic lesions in primary biliary cirrhosis. Gut 2006; 55:1795.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Floreani A, Cazzagon N, Franceschet I, et al. Metabolic syndrome associated with primary biliary cirrhosis. J Clin Gastroenterol 2015; 49:57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poupon RE, Ouguerram K, Chrétien Y, et al. Cholesterol-lowering effect of ursodeoxycholic acid in patients with primary biliary cirrhosis. Hepatology 1993; 17:577.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Balan V, Dickson ER, Jorgensen RA, Lindor KD. Effect of ursodeoxycholic acid on serum lipids of patients with primary biliary cirrhosis. Mayo Clin Proc 1994; 69:923.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Del Puppo M, Galli Kienle M, Crosignani A, et al. Cholesterol metabolism in primary biliary cirrhosis during simvastatin and UDCA administration. J Lipid Res 2001; 42:437.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hirschfield GM, Mason A, Luketic V, et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology 2015; 148:751.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheung AC, Lapointe-Shaw L, Kowgier M, et al. Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes. Aliment Pharmacol Ther 2016; 43:283.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Corpechot C, Chazouillères O, Rousseau A, et al. A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis. N Engl J Med 2018; 378:2171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rudic JS, Poropat G, Krstic MN, et al. Bezafibrate for primary biliary cirrhosis. Cochrane Database Syst Rev 2012; 1:CD009145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liberopoulos EN, Florentin M, Elisaf MS, et al. Fenofibrate in primary biliary cirrhosis: a pilot study. Open Cardiovasc Med J 2010; 4:120.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reig A, Sesé P, Parés A. Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response. Am J Gastroenterol 2018; 113:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ritzel U, Leonhardt U, Näther M, et al. Simvastatin in primary biliary cirrhosis: effects on serum lipids and distinct disease markers. J Hepatol 2002; 36:454.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abu Rajab, MA, Kaplan, MM . Statin use in primary biliary cirrhosis: Are they safe? (abstract). Gastroenterology 2007; 132:A732.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stojakovic T, Putz-Bankuti C, Fauler G, et al. Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid. Hepatology 2007; 46:776.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 3602 Version 30.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12117892" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18759822" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Risk of cardiovascular and cerebrovascular events in primary biliary cirrhosis: a population-based cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26364546" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Primary biliary cirrhosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31506216" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Patterns of serum lipids derangements and cardiovascular risk assessment in patients with primary biliary cholangitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17928612" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Hypercholesterolemia in primary biliary cirrhosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15314101" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Lipoprotein-X reduces LDL atherogenicity in primary biliary cirrhosis by preventing LDL oxidation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17240380" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35787279" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Atypical primary biliary cholangitis results in vanishing bile duct syndrome with cutaneous xanthomas: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4054519" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Lipoprotein abnormalities in primary biliary cirrhosis. Association with hepatic lipase inhibition as well as altered cholesterol esterification.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16632556" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Hypercholesterolaemia is not associated with early atherosclerotic lesions in primary biliary cirrhosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24231935" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Metabolic syndrome associated with primary biliary cirrhosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8477962" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Cholesterol-lowering effect of ursodeoxycholic acid in patients with primary biliary cirrhosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7934188" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Effect of ursodeoxycholic acid on serum lipids of patients with primary biliary cirrhosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11254756" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Cholesterol metabolism in primary biliary cirrhosis during simvastatin and UDCA administration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25500425" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26559762" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29874528" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22259000" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Bezafibrate for primary biliary cirrhosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20556204" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Fenofibrate in primary biliary cirrhosis: a pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29016567" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11943414" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Simvastatin in primary biliary cirrhosis: effects on serum lipids and distinct disease markers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Statin use in primary biliary cirrhosis: Are they safe? (abstract)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17668874" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
